Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Commencement of share buyback programme

3 Jun 2026 07:00

RNS Number : 7308G
Elementis PLC
03 June 2026
 

3 June 2026

 

Elementis plc

 

Commencement of share buyback programme

 

Further to the announcement of 2 June 2026, Elementis plc ("Elementis" or the "Company"), announces that from today it will commence a programme to purchase up to approximately £25m (equivalent to approximately $35m) of the Company's ordinary shares of 5 pence each (the "Ordinary Shares") (the "Programme") by no later than 28 February 2027.

The purpose of the Programme is to reduce the Company's share capital and accordingly the Company intends to cancel the majority of shares repurchased, with a proportion retained in treasury to meet obligations under the Company's employee share scheme. Any purchases will be conducted in compliance with the relevant conditions for trading, restrictions regarding time and volume, disclosure and reporting obligations, and price conditions. The Company confirms that it currently has no unpublished Inside Information.

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 29 April 2026 which authority will expire at the end of the next Annual General Meeting of the Company in 2027 or, if earlier, 1 July 2027 ("2026 Authority"). The Company has appointed Rothschild & Co Global Markets Solutions Limited ("Rothschild & Co") to manage the Programme and has issued an irrevocable instruction to Rothschild & Co to continue to manage the Programme, within pre-set parameters, during any closed period. This appointment will continue until 28 February 2027 (unless terminated earlier in accordance with its terms), subject to automatic extension in certain circumstances. The Programme will be carried out on the London Stock Exchange and other trading venues[1] and executed within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as each forms part of domestic law under the European Union (Withdrawal) Act 2018, including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019) and Chapter 9 of the UK Listing Rules of the Financial Conduct Authority. Transactions undertaken under the Programme will be disclosed by way of a Regulatory Information Service announcement on a weekly basis.

The aggregate maximum consideration payable by the Company in respect of the purchase of shares under the Programme up to 28 February 2027 is up to approximately £25m (equivalent to approximately $35m). The maximum number of shares that may be purchased under the Programme is 56,931,567 (being the number of shares able to be purchased under the 2026 Authority).

 

Enquiries

Investors:

Zeeshan Maqbool, Elementis plc

Tel: +44 (0) 7553 340 380

Press:

Martin Robinson, Giles Kernick, Teneo

Tel: +44 (0) 20 7353 4200

 

 

About Elementis

Elementis is a global specialty chemicals company listed on the London Stock Exchange. The Group employs c.1,000 across 18 global locations. As recognised innovation leaders with deep expertise in rheology (the science of flow), and formulation solutions, we develop distinctive solutions and products to improve performance, achieve smoother production, and enhance sustainability credentials for customers across a range of industries. The Group also owns and operates one of the largest known commercial high-quality hectorite mines in the world. Hectorite is a special, high-purity clay mineral rich in magnesium and lithium, known for its ability to control viscosity, stabilise formulations, and deliver smooth, consistent textures that make it ideal for clean-label, high-performance formulations. 

Elementis is composed of two focused, high-margin businesses: Personal Care and Coatings. The Personal Care business manufactures natural and synthetic rheology modifiers to deliver premium product performance for personal care applications in skin care and cosmetics, as well as active ingredients for antiperspirants. Within Coatings, Elementis develops and manufactures rheology modifiers and premium performance additives for decorative and industrial paints and coatings. The Coatings business also includes our Energy and Adhesives, Sealants and Construction additives businesses.


[1] Turquoise, Chi-X Europe and BATS Trading Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKBBNOBKDFAK
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.